The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex, strategic acquisitions from Eli Lilly, and late-stage successes validating the commercial potential of novel mechanisms. However, the clinical pathway […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches. Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. […]

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 - 29 January 2026, this essential meeting unites 170+ senior leaders across R&D, CMC (Chemistry, Manufacturing, and Controls), Regulatory […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings together senior decision-makers from biopharma, biotech innovators, investors, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. As the aging population grows, […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater. In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting the field in San Diego February 3-5, 2026 for 3 days of data- and strategy-driven presentations and networking sessions, the 10th Liquid Biopsy for Precision […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential to reshape oncology care, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. Returning as the longest-standing […]

Across pharma, biotech, chemicals, FMCG, and beyond, laboratory leaders are facing the same challenge: how to turn the vision of a smart, digital lab into reality. From harmonising data and making it AI-ready to unlocking the true value of automation, the journey from concept to execution is complex - but critical. SmartLab Exchange Europe 2026 […]

The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define, benchmark, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. As Medical Affairs cements its role as the strategic bridge between R&D and commercialization, the pressure to quantify and communicate impact has never been […]

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI transforms big data analysis, it has never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, […]

Now in its 8th year, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility, embedding AI and analytics, and building future-ready workforces - […]

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnerships & Capital With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked […]

The 7th Annual AI in Drug Discovery Conference, hosted by SAE Media Group, takes place 9-10 March 2026 at Hilton London Kensington. This event explores how AI, machine learning, and automation are transforming drug discovery – from generative design and molecular modelling to clinical trial optimisation. Attendees will hear from Big Pharma and Biotech senior […]

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as […]

The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune strategies. As the biopharma industry accelerates its focus on immuno-oncology and cell therapy, this is the only summit that brings together leading experts and decision-makers […]

Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases, this summit provides an exclusive platform for uncovering the next wave of breakthroughs in B-cell biology and beyond. The event brings together leading immunologists, clinical […]

Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence, fresh investment, and major acquisitions signalling a return to growth, the industry is refocusing on overcoming the critical barriers of safety, efficacy, scalability, […]

Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. The […]

Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications. Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture […]

The SmartLab Exchange USA is an exclusive, invitation-only event designed for senior laboratory, R&D, and digital transformation leaders across pharma, biotech, chemicals, FMCG, and food & beverage. This two-day forum brings together more than 60 decision-makers to tackle one of the industry’s most pressing challenges: how to make lab digitalization work in practice. Every lab […]

As part of SAE’s leading PFS Series, the 2026 conference will once again bring together top experts, industry leaders, and innovators for a three-days of key insights and networking. The conference will feature a comprehensive pre-conference focus day dedicated to advancements in device design, followed by a dynamic two-day main conference featuring keynote plenaries, interactive panel discussions, and specialized topic streams covering the […]

The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, and CMC leaders, the summit brings together senior experts from across pharma and biotech to advance analytical rigor, deepen product understanding, and enable regulatory-ready ADC […]

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy. To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation […]

Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between […]

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies, momentum in the GPCR space continues to build. The race is on to […]

Patient engagement has shifted from a “nice to have” to a strategic necessity. With regulators expecting defensible evidence, executives demanding clear ROI, and funding under tighter scrutiny, every engagement initiative must show measurable value. Yet many organizations still struggle to demonstrate the true impact of their work. The 3rd Measuring Patient Engagement Summit is the […]